The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).
Thomas Joseph Kaley
No relevant relationships to disclose
Elena Pentsova
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
No relevant relationships to disclose
Ingo K. Mellinghoff
No relevant relationships to disclose
Craig Nolan
No relevant relationships to disclose
Igor T. Gavrilovic
No relevant relationships to disclose
Lisa Marie DeAngelis
No relevant relationships to disclose
Mario E. Lacouture
No relevant relationships to disclose
Eric C. Holland
No relevant relationships to disclose
Andrew B. Lassman
Consultant or Advisory Role - Abbott Laboratories; CampusBio; Genentech; Kyowa Hakko Kirin; Merck; Novartis; RadMD; Roche
Honoraria - Merck
Research Funding - Agenus; AstraZeneca; Boehringer Ingelheim; Celldex; Genentech; MedImmune; Merck; NCI; Northwest Biotherapeutics; Novocure; Pfizer
Other Remuneration - Abbott Laboratories; CampusBio; Genentech; Kyowa Hakko Kirin; Merck; Novartis; RadMD; Roche